Combining a molecular profile with a clinical and pathological profile: Biostatistical considerations

References

• Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. TSW Urology 2006; 1(S2)15–23
   Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466–77
   PubMed Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 2004; 45: 292–6
   PubMed Web of Science ®Google Scholar
• Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 2005; 66(S6A)64–74
   PubMedGoogle Scholar
• Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007; 52: 1601–9
   PubMed Web of Science ®Google Scholar
• Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23: 7332–41
   PubMed Web of Science ®Google Scholar
• Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007; 96: 1155–8
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005; 21: 3017–24
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Murthy KRK, Michiels S, Ploner A. Bias in the estimation of false discovery rate in microarray studies. Bioinformatics 2005; 21: 3865–72
   PubMed Web of Science ®Google Scholar
• Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488–92
   PubMed Web of Science ®Google Scholar
• Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002; 97: 77–87
   Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005; 41: 1690–6
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. What do we mean by validating a prognostic model?. Statist Med 2000; 19: 453–73
   PubMed Web of Science ®Google Scholar
• Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005; 21: 3301–7
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Denaxa-Kyza D, Ioannidis JPA. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559–79
   PubMed Web of Science ®Google Scholar
• Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95: 634–5
   PubMedGoogle Scholar
• Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882–90
   PubMed Web of Science ®Google Scholar
• Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004; 10: 822–4
   PubMed Web of Science ®Google Scholar
• Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 2007; 43: 745–51
   PubMed Web of Science ®Google Scholar
• Schemper M, Stare J. Explained variation in survival analysis. Statist Med 1996; 15: 1999–2012
   PubMed Web of Science ®Google Scholar
• Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000; 56: 249–55
   PubMed Web of Science ®Google Scholar
• Schemper M. Predictive accuracy and explained variation. Statist Med 2003; 22: 2299–308
   PubMed Web of Science ®Google Scholar
• Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003; 170: S6–S10
   PubMed Web of Science ®Google Scholar
• Pintilie M. Competing risks: a practical perspective. John Wiley and Sons, Chichester 2006
   Google Scholar
• Harrell FE, Lee KL, Mark DB. Tutorial in Biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 1996; 15: 361–87
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61: 92–105
   PubMed Web of Science ®Google Scholar
• Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111–6
   PubMed Web of Science ®Google Scholar
• Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol 2008; 54: 41–53
   PubMed Web of Science ®Google Scholar
• Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173: 1518–25
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254–62
   PubMed Web of Science ®Google Scholar
• International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967–72.
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Shariat SF, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176: 1354–62
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12: 6663–76
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315–25
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med 2008; 27: 157–72
   PubMed Web of Science ®Google Scholar